| scholarly article | Q13442814 |
| P2093 | author name string | Francesca Rossi | |
| Diego Strianese | |||
| P2860 | cites work | Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity | Q26852013 |
| Autoimmunity and Graves' disease | Q27022771 | ||
| Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. | Q27691806 | ||
| MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials | Q28077018 | ||
| Antiinflammatory action of glucocorticoids--new mechanisms for old drugs | Q28278037 | ||
| Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial | Q30481543 | ||
| Germinal center selection and the development of memory B and plasma cells | Q34268133 | ||
| B-cell biology and development | Q34331269 | ||
| Teprotumumab for Thyroid-Associated Ophthalmopathy. | Q34556184 | ||
| Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study | Q34747393 | ||
| A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. | Q34782210 | ||
| Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. | Q35055076 | ||
| Randomized controlled trial of rituximab in patients with Graves' orbitopathy | Q35055124 | ||
| Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor | Q35992560 | ||
| Axial Globe Position Measurement: A Prospective Multicenter Study by the International Thyroid Eye Disease Society. | Q35995565 | ||
| Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment | Q36525240 | ||
| Avoiding surgery for thyroid eye disease | Q36613471 | ||
| A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy | Q36817224 | ||
| Clinical review: Clinical utility of TSH receptor antibodies | Q36885833 | ||
| Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies | Q36970632 | ||
| Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. | Q37017174 | ||
| Immune mechanisms in thyroid eye disease. | Q37254482 | ||
| Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype | Q37296579 | ||
| The type 1 insulin-like growth factor receptor pathway | Q37300867 | ||
| Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. | Q37363607 | ||
| Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. | Q37417167 | ||
| Thyroid-associated orbitopathy: who and how to treat | Q37425768 | ||
| Methotrexate for the treatment of thyroid eye disease | Q37616156 | ||
| Memory B and memory plasma cells | Q37781393 | ||
| Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity | Q37829150 | ||
| Decisions on the road to memory | Q38086164 | ||
| Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. | Q38351966 | ||
| Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy | Q38877933 | ||
| Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids? | Q39041665 | ||
| Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease | Q39167512 | ||
| Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease | Q39430686 | ||
| Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy | Q40893670 | ||
| Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO). | Q41096678 | ||
| Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy | Q41657253 | ||
| The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity | Q41876450 | ||
| The critical role of Shc in insulin-like growth factor-I-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes | Q42801077 | ||
| Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes | Q43867818 | ||
| Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. | Q45096631 | ||
| Clinical Response to Tocilizumab in Severe Thyroid Eye Disease | Q46188153 | ||
| Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy | Q46585048 | ||
| Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease | Q46906161 | ||
| Analysis of orbital T cells in thyroid-associated ophthalmopathy | Q47901537 | ||
| Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. | Q49360082 | ||
| Soft Tissue Metrics in Thyroid Eye Disease: An International Thyroid Eye Disease Society Reliability Study. | Q49712817 | ||
| Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience. | Q50701679 | ||
| Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. | Q51852266 | ||
| Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. | Q52950179 | ||
| Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy. | Q53057871 | ||
| Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. | Q53555780 | ||
| Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. | Q53611171 | ||
| Adrenal reserve following treatment of Graves' orbitopathy with intravenous glucocorticoids. | Q53634232 | ||
| Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. | Q53758474 | ||
| Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. | Q54280456 | ||
| Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy | Q58109526 | ||
| Infliximab: A Novel Treatment for Sight-Threatening Thyroid Associated Ophthalmopathy | Q60207430 | ||
| Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association | Q60604183 | ||
| Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study | Q68187821 | ||
| Azathioprine in the treatment of thyroid-associated ophthalmopathy | Q68713064 | ||
| Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy | Q69288448 | ||
| Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy | Q71612410 | ||
| Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue | Q72226506 | ||
| Thyrotropin receptor expression in cultured Graves' orbital preadipocyte fibroblasts is stimulated by thyrotropin | Q74336335 | ||
| Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy | Q77351739 | ||
| The effect of etanercept on Graves' ophthalmopathy: a pilot study | Q81024281 | ||
| Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway | Q81163093 | ||
| Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids | Q82359524 | ||
| Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy | Q83216077 | ||
| Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways | Q85211682 | ||
| Treatment of active corticosteroid-resistant graves' orbitopathy | Q87246219 | ||
| Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial | Q90775985 | ||
| P433 | issue | 2 | |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 191-199 | |
| P577 | publication date | 2019-01-04 | |
| P1433 | published in | Eye | Q10278937 |
| P1476 | title | Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy | |
| P478 | volume | 33 |
Search more.